6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL

MLA

David W. Boulton, et al. “6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL.” Diabetes, vol. 68, June 2019. EBSCOhost, https://doi.org/10.2337/db19-6-lb.

APA

David W. Boulton, Marcus Thuresson, James A. Ruggles, John B. Buse, Srinivas Bachina, C. David Sjöström, Lindsay E. Clegg, Hiddo L. Heerspink, Robert C. Penland, Adrian F. Hernandez, Stephanie Gustavson, Rury R. Holman, & Robert J. Mentz. (2019). 6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL. Diabetes, 68. https://doi.org/10.2337/db19-6-lb

Chicago

David W. Boulton, Marcus Thuresson, James A. Ruggles, John B. Buse, Srinivas Bachina, C. David Sjöström, Lindsay E. Clegg, et al. 2019. “6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL.” Diabetes 68 (June). doi:10.2337/db19-6-lb.